Dinamarca -
dinamarquês -
Lægemiddelstyrelsen (Danish Medicines Agency)
divifarm 25 mikrogram filmovertrukne tabletter
orifarm generics a/s - cholecalciferol - filmovertrukne tabletter - 25 mikrogram
Dinamarca -
dinamarquês -
Lægemiddelstyrelsen (Danish Medicines Agency)
alfacalcidol "alternova" 0,25 mikrogram kapsler, bløde
alternova a/s - alfacalcidol - kapsler, bløde - 0,25 mikrogram
Dinamarca -
dinamarquês -
Lægemiddelstyrelsen (Danish Medicines Agency)
etalpha 0,25 mikrogram kapsler, bløde
cheplapharm arzneimittel gmbh - alfacalcidol - kapsler, bløde - 0,25 mikrogram
Dinamarca -
dinamarquês -
Lægemiddelstyrelsen (Danish Medicines Agency)
etalpha 0,25 mikrogram kapsler, bløde
2care4 aps - alfacalcidol - kapsler, bløde - 0,25 mikrogram
Dinamarca -
dinamarquês -
Lægemiddelstyrelsen (Danish Medicines Agency)
alfacalcidol "aristo" 0,25 mikrogram kapsler, bløde
aristo pharma gmbh - alfacalcidol - kapsler, bløde - 0,25 mikrogram
Dinamarca -
dinamarquês -
Lægemiddelstyrelsen (Danish Medicines Agency)
alfacalcidol "orifarm" 0,25 mikrogram kapsler, bløde
orifarm generics a/s - alfacalcidol - kapsler, bløde - 0,25 mikrogram
Dinamarca -
dinamarquês -
Lægemiddelstyrelsen (Danish Medicines Agency)
alfacalcidol "strides" 0,25 mikrogram kapsler, bløde
strides pharma (cyprus) limited - alfacalcidol - kapsler, bløde - 0,25 mikrogram
Dinamarca -
dinamarquês -
Lægemiddelstyrelsen (Danish Medicines Agency)
divisun 25 mikrogram tabletter
viatris aps - cholecalciferol - tabletter - 25 mikrogram
Dinamarca -
dinamarquês -
Lægemiddelstyrelsen (Danish Medicines Agency)
rayaldee 30 mikrogram depotkapsler, bløde
vifor fresenius medical care renal pharma france - calcifediol - depotkapsler, bløde - 30 mikrogram
União Europeia -
dinamarquês -
EMA (European Medicines Agency)
crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - narkotika til behandling af knoglesygdomme - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.